- Bacteriophage therapy, which leverages viruses that infect and kill specific bacteria, is becoming an increasingly essential alternative to antibiotics in Europe’s fight against antimicrobial resistance, particularly in both clinical and research-based healthcare environments due to its precision, safety, and ability to treat resistant infections
- The growing demand for bacteriophage therapy is primarily fueled by the alarming rise in multidrug-resistant bacterial infections, supportive European health policies, and expanding investments in personalized medicine and biologics
- Germany dominated the bacteriophage therapy market with the largest revenue share of 30.5% in 2024, driven by its advanced healthcare infrastructure, government-backed innovation programs, and strong presence of biotechnology firms engaged in phage research and development
- Poland is expected to be the fastest growing country in the Europe bacteriophage therapy market during the forecast period due to its historic foundation in phage therapy, increasing clinical application, and growing international collaborations in antimicrobial research
- The wound and skin infections segment dominated the Europe bacteriophage therapy market with a market share of 39% in 2024, attributed to high efficacy in treating chronic, antibiotic-resistant wounds and increasing clinical adoption in post-surgical care
